INS and type 2 diabetes mellitus: According to a prior clinical trial evaluating the Dexcom G6 CGM (Dexcom, Inc., San Diego, CA, USA) device in patients with type 2 diabetes mellitus not receiving insulin therapy, CGM use was associated with significant improvements in glycemic control as well as multiple cardiometabolic risk factors, including reductions in BMI, triglycerides, blood pressure, and total cholesterol [39].